Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.

Background: Dose reduction in obese cancer patients has been replaced by fully weight-based dosing recommendations. No data, however, are available on the effects of dose reduction in obese stage III colon cancer patients undergoing adjuvant chemotherapy.
Methods: Survival outcomes and toxicity data of obese (body mass index [BMI] ≥30 kg/m ² ), stage III colon cancer patients treated within the phase III PETACC 3 trial comparing leucovorin, 5-FU (LV5FU2) with LV5FU2 plus irinotecan were analysed retrospectively according to chemotherapy dosing at first infusion (i.e. fully weight-based dosed - versus dose-reduced group). Multivariate analyses on relapse free survival (RFS) and overall survival (OS) were conducted to adjust for baseline prognostic factors using Cox regression model.
Results: 13.4% (280 of 2094 patients) had a BMI ≥ 30 kg/m ² , and 5.3% had both a BMI ≥ 30 kg/m ² and a body surface area (BSA) ≥2 m ² . Dose reductions occurred in 16.1% of patients with a BMI ≥ 30 kg/m ² and 32.4% with BMI ≥ 30 kg/m ² and BSA ≥ 2 m ² , respectively. In patients with BMI ≥ 30 kg/m ² , multivariate analysis demonstrated a trend towards better RFS in the fully dosed compared to the dose-reduced group (Hazard ratio (HR): 0.69, 95% CI: 0.43-1.09; p = 0.11); however, there was no statistically significant difference in OS. In patients with BMI ≥ 30 kg/m ² and BSA ≥ 2 m ² , multivariate analysis demonstrated better RFS in fully dosed compared with dose-reduced patients (HR: 0.48, 95% CI: 0.27-0.85; p = 0.01) and a strong trend towards better OS (HR: 0.53, 95% CI: 0.28-1.01; p = 0.052). This group comprised predominantly of men.
Conclusions: Data support the recommendation of using fully dosed chemotherapy for the adjuvant treatment in obese patients with colon cancer.
(Copyright © 2018 Elsevier Ltd. All rights reserved.)